文献速递神经PETMR

[18F]DASA-23 PET/MRI 在初诊和复发高级别胶质瘤中的评估

[18F]DASA-23 PET/MRI evaluation in newly-diagnosed and recurrent high-grade glioma.
PubMed 文献 · Neuroradiology · 2026-04-01

这项前瞻性初步研究纳入4名健康对照和9例高级别胶质瘤患者,评估[18F]DASA-23 PET/MRI的诊断性能及其摄取与生存的关系。基线[18F]DASA-23 PET诊断高级别胶质瘤的敏感度为0.78、特异度为1.00、准确度为0.85;治疗后随访中肿瘤与本底比值SUVmax与无进展生存期显著负相关(r=-0.91,p=0.03)。[18F]DASA-23摄取与MR灌注指标无显著关联,且与强化及非强化T2-FLAIR高信号体积重叠有限。

要点

  • 基线[18F]DASA-23 PET诊断高级别胶质瘤的敏感度为0.78、特异度为1.00、准确度为0.85。
  • 治疗后随访[18F]DASA-23 PET的肿瘤与本底比值SUVmax与无进展生存期显著负相关(r=-0.91,p=0.03)。
  • [18F]DASA-23摄取与MR灌注指标无显著关联,与强化及非强化T2-FLAIR高信号体积重叠有限。

核心结论

  • 这项初步研究显示[18F]DASA-23 PET对高级别胶质瘤诊断性能良好;治疗后摄取经进一步研究可能作为评估疗效和患者预后的标志物。

研究设计与样本

  • 前瞻性初步研究,纳入4名健康对照和9例高级别胶质瘤患者,接受[18F]DASA-23 PET/MRI,由3名核医学医师独立判定有无颅内局灶性摄取。

关键影像表现/征象

  • 基线[18F]DASA-23 PET诊断高级别胶质瘤的敏感度为0.78、特异度为1.00、准确度为0.85。
  • 5例患者治疗后平均46天随访[18F]DASA-23 PET的肿瘤与本底比值SUVmax与无进展生存期显著负相关(r=-0.91,p=0.03)。
  • MR DSC衍生的nCBV和ASL衍生的nCBFmax与[18F]DASA-23摄取无显著关联。
  • 在[18F]DASA-23摄取的感兴趣区内,20.2%体积为T1增强后强化,28.3%体积为非强化T2-FLAIR高信号,两者体积无显著差异。

诊断标准与关键数值

  • 基线[18F]DASA-23 PET诊断高级别胶质瘤:敏感度0.78、特异度1.00、准确度0.85。
  • 治疗后平均46天随访[18F]DASA-23 PET的TBRmax与PFS:r=-0.91,p=0.03。
  • [18F]DASA-23摄取区体积构成:T1增强后强化占20.2%,非强化T2-FLAIR高信号占28.3%,两者无显著差异。

临床应用与阅片要点

  • 作者认为[18F]DASA-23 PET治疗后摄取经进一步研究可能作为评估疗效和患者预后的标志物。
  • [18F]DASA-23 PET与MR灌注标志物无显著关系,且与强化及非强化T2-FLAIR高信号重叠有限,作者提出未来更大样本[18F]DASA-23 PET研究可能发现MR未完全捕捉的临床相关信息。

局限性

  • 本研究的结论将[18F]DASA-23 PET治疗后摄取作为疗效和预后标志物的可能性表述为「may with further research be useful」,即需进一步研究。
  • 作者提出未来需更大患者样本的[18F]DASA-23 PET研究,以可能发现MR未完全捕捉的临床相关信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: High-grade gliomas pose significant diagnostic imaging challenges in their initial diagnosis, evaluation of treatment-related change versus recurrent/progressive disease, and prognostication. 1-((2-fluoro-6-[18F]fluorophenyl)sulfonyl)-4-((4-methoxyphenyl)sulfonyl)piperazine ([18F]DASA-23) which binds pyruvate kinase M2 (PKM2), an important enzyme in glycolysis, was developed to probe the metabolic activity of high-grade gliomas. This pilot study sought to evaluate [18F]DASA-23 PET’s diagnostic performance in high-grade gliomas, how its uptake over time is associated with survival, and its relationship with conventional MR findings.

MATERIALS AND METHODS: This prospective pilot study enrolled healthy controls and patients with high-grade gliomas who received [18F]DASA-23 PET/MRI’s. In the latter group, scans were performed at the time of initial diagnosis or recurrence, with a sub-group also receiving follow-up scans during their therapy course. Three nuclear medicine physicians independently adjudicated the presence or absence of focal intracranial [18F]DASA-23 uptake, from which the sensitivity, specificity, accuracy, positive predictive value, and negative predictive value were determined. For patients with tumors, tumor-to-background SUVmax was calculated and correlated with progression-free survival (PFS). Correlation analysis between MRI perfusion parameters and [18F]DASA-23 TBRmax was also performed. As an exploratory analysis, the amount of [18F]DASA-23 uptake overlap with sites of both MRI T1 post-contrast enhancement and non-enhancing T2-FLAIR hyperintense signal about the resection cavity pre-therapy was determined.

RESULTS: Four healthy controls and nine patients with high-grade gliomas were included in this study. The baseline [18F]DASA-23 PET demonstrated a sensitivity of 0.78, specificity of 1.00, and accuracy of 0.85 in the diagnosis of high-grade glioma. The follow-up [18F]DASA-23 PET exams in 5 patients at a mean of 46 days after initiation of therapy showed tumor to background ratio SUVmax (TBRmax) was significantly inversely correlated with PFS (r = -0.91, p = 0.03). MR dynamic contrast susceptibility (DSC) derived normalized cerebral blood volume (nCBV) and arterial spin labeling (ASL) derived normalized cerebral blood flow max (nCBFmax) were not significantly associated with [18F]DASA-23 uptake. Within the [18F]DASA-23 uptake regions of interest, 20.2% of the volume was occupied by T1 post-contrast enhancement, and 28.3% of the volume was non-enhancing T2 FLAIR hyperintensity, with no significant difference in the volume of enhancement and non-enhancing T2 FLAIR hyperintensity.

CONCLUSION: This pilot study demonstrated favorable [18F]DASA-23 PET diagnostic performance in the diagnosis of high-grade gliomas, and its uptake after initiation of therapy may with further research be useful as a marker to evaluate treatment efficacy and patient prognosis. Additionally, the absence of a significant relationship between [18F]DASA-23 uptake and MR perfusion markers, and [18F]DASA-23 PET’s limited overlap with enhancement and non-enhancing T2 FLAIR hyperintensity raises the possibility that future [18F]DASA-23 PET studies with larger patient samples could uncover clinically relevant information not fully captured with MR alone.

SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00234-026-03956-3.

来源:Neuroradiology,查看原文。版权归原作者所有。

引用

  1. Khalaf A, Naya L, Flynt L, et al. [18F]DASA-23 PET/MRI evaluation in newly-diagnosed and recurrent high-grade glioma. Neuroradiology. 2026. PMID: 41920333. doi:10.1007/s00234-026-03956-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。